Stay updated on Nivolumab and Ipilimumab in ACC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Ipilimumab in ACC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the funding-lapse notice (previous Revision: v3.4.1).
    Difference
    0.4%
    Check dated 2026-02-11T02:16:41.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Notice about government funding and NIH site operations added. The site version updated from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T00:36:38.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary toggle option and updated several metadata labels, including capitalization changes to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'. The revision identifier was updated to v3.4.0 (from v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T00:30:27.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    A new Revision: v3.3.4 label was added and the previous Revision: v3.3.3 label was removed, indicating a minor site revision. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T01:54:52.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    An updated status block was added, displaying Northwestern University as sponsor and the last known status with a verification date (2023-12).
    Difference
    0.4%
    Check dated 2026-01-07T00:33:55.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Locations section is reorganized under a general 'Locations' header and now lists Illinois as a study site, replacing the previous 'Illinois Locations' heading. The footer 'HHS Vulnerability Disclosure' link was removed and the revision label updated from v3.3.2 to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T13:27:31.000Z thumbnail image

Stay in the know with updates to Nivolumab and Ipilimumab in ACC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.